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Abstract: Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mes-
enchymal origin. This paper reviews the current status of systemic treatment in advanced and 
metastatic soft tissue sarcomas, with an emphasis on trabectedin. Trabectedin is a unique type of 
chemotherapeutic agent with multiple potential mechanisms of action. We discuss the putative 
mechanisms, as well as the toxicity and administration schedules of trabectedin, followed by its 
efficacy in first-line systemic therapy and beyond first-line systemic therapy.
Keywords: soft-tissue sarcoma, trabectedin, chemotherapy
Introduction
Soft-tissue sarcomas (STS) are a heterogeneous group of rare solid tumors of mesen-
chymal origin. STS account for approximately 1% of adult cancers, with an annual 
incidence of 5 per 100,000 inhabitants.1 Although STS can arise anywhere in the 
body, the majority occur in the limb or limb girdle (60%) or within the abdomen 
(retroperitoneal and intraperitoneal, 20%).2 Over 50 different subtypes of STS have 
been identified in the latest World Health Organization classification of tumors of soft 
tissue and bone based on clinical insights, histopathology, and molecular biology.3 The 
most common subtypes, together accounting for about three-quarters of all STS, are 
undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, myxofibrosar-
coma, synovial sarcoma, and malignant peripheral nerve sheath tumors.3 Molecular 
diagnostics are increasingly used to identify histological subtypes of STS.4 The etiol-
ogy of most STS is unknown, but in a minority of STS patients an association exists 
with irradiation,5,6 chronic lymphangioedema,7 viral infections (eg, HHV-8 in Kaposi 
sarcoma),8 and known genetic susceptibility (eg, malignant peripheral nerve sheath 
tumors in neurofibromatosis type).9 About 10% of patients have detectable metastases 
(most common in the lungs) at diagnosis of the primary tumor and, depending on the 
grade, overall, one-third to half of patients with STS die due to tumor-related diseases.3
In this review, we focus on the currently available systemic treatment strategies for 
advanced or metastatic STS in adults, with an emphasis on trabectedin.
Current standard of care for advanced STS: 
in a glance
Localized STS have traditionally been managed by wide excisional surgery with or 
without radiotherapy. The use of chemotherapy or targeted therapy has mostly been 
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reserved for advanced disease, aiming to achieve disease pal-
liation and control. The profound heterogeneity of STS sub-
types complicates the conduct and interpretation of clinical 
trials. Within the group of STS, subtypes have been identified 
as less or more sensitive to systemic therapy, but most studies 
recruit all histological subtypes and are not powered for this 
kind of subgroup analyses. Therefore, most STS subtypes 
are treated in the same way. Selected sarcomas, including 
gastrointestinal stromal tumors (GIST), Ewing family of 
tumors, and embryonal or alveolar rhabdomyosarcomas, are 
exceptions that are effectively treated with specific systemic 
therapies and are excluded from this review.10
Cytotoxic chemotherapy is the mainstay of therapy for 
advanced or metastatic STS (Table 1). Targeted therapy, in 
particular pazopanib,11 currently has a modest role but is 
under extensive investigation and is likely to gain further 
importance in advanced STS. A number of early trials uti-
lizing immunotherapy have been initiated. A recent review 
summarizes gold standard and novel therapies for advanced 
STS.12,13
First-line systemic therapy
Doxorubicin or combination of doxorubicin plus 
ifosfamide
The anthracycline doxorubicin is considered to be the standard 
first-line systemic therapy for advanced STS.10,12 Doxorubicin 
is administered intravenously (IV) at a dose of 60–75 mg/
m2 every 3 weeks. This drug has dose-limiting cumulative 
cardiotoxicity. Response rates for single-agent treatment 
with doxorubicin vary between 16% and 27%. Median 
overall survival (OS) varies between 7.7 and 12 months.14 
In 2003, a Cochrane review based on eight randomized 
controlled trials compared doxorubicin as single agent to 
 doxorubicin-based  combination therapy (of which two trials 
were with  doxorubicin and ifosfamide). For the combination 
schedules, a response rate varying between 14% and 34% was 
found with a median OS of 7.3–12.7 months. It was concluded 
that doxorubicin-based combinations add a marginal increase 
in response rate, at the expense of increased toxic effects, but 
no significant improvement in OS.14 In 2014, the EORTC 
STSBG 62012 study compared single-agent doxorubicin to 
the combination of doxorubicin and ifosfamide with com-
parable results: a response rate of 13.6% vs 26.5%, median 
progression-free survival (PFS) of 4.6 vs 7.4 months, and no 
significant difference in median OS (12.8 vs 14.3 months) but 
significantly more adverse events in the combination arm.15 
Therefore, the combination of doxorubicin and ifosfamide is 
recommended when a volume response is the primary aim, 
eg, in cases of symptomatic disease (pain and dysfunction) 
or induction treatment before radical surgery.
A Phase III trial randomizing patients with advanced/
metastatic STS to receive first-line therapy with either doxo-
rubicin + palifosfamide or doxorubicin + placebo reported 
no difference in PFS and OS between the two arms. Further-
more, another Phase III trial randomizing patients to receive 
doxorubicin + evofosfamide or single-agent doxorubicin 
also reported no difference in outcome (NCT01440088). 
Therefore, on the basis of the results of these Phase III trials, 
single-agent doxorubicin is generally regarded as standard 
first-line therapy for patients with advanced/metastatic STS.
Currently, the combination of doxorubicin and the 
platelet-derived growth factor receptor alpha antibody 
olaratumab is under investigation as first-line treatment for 
all STS subtypes. In the Phase II study, up to eight cycles of 
Table 1 Systemic therapies for advanced or metastatic STS, other than trabectedin
Drug Reference ORR (%) mPFS 
(months)
mOS 
(months)
Most commonly reported adverse events
Doxorubicin 14 16–27 4.6 7.7–12.8 Leucopenia, neutropenia
Doxorubicin + ifosfamide 15 14–34 7.4 7.3–14.3 Leucopenia, neutropenia, febrile neutropenia, anemia, 
thrombocytopenia, nausea, vomiting, encephalopathy
Gemcitabine + docetaxela 17–21 5–52 6–6.2 16–26.9 Anemia, fatigue, alopecia, thrombocytopenia, dyspnea, 
neutropenia
Taxanesb 22–27 7–89 – 7–9.5 Anemia, neutropenia, fatigue, neuropathy
Cyclophosphamide + prednisone 29 26.9 6.8 – Lymphopenia, anemia, thrombocytopenia
Ifosfamide 30–34 20–25 – 12 Fatigue, nausea, vomiting
Gemcitabine 35–39 3.2–27 1.5–6.3 7.2–20 Hematologic toxicities, increased ALT levels, myalgia, rash
Dacarbazine 40–44 4–18 2 8.2–11.5 Hematologic toxicities, fatigue, nausea vomiting, stomatitis
Eribulinc 44 4 2.6 13.5 Fatigue, nausea, alopecia, constipation, leukopenia, 
neutropenia, anemia
Pazopanib 11 6 4.6 12.5 Fatigue, diarrhea, nausea, weight loss, hypertension
Notes: aIn (mainly uterine) leiomyosarcoma, bin angiosarcoma, cin leiomyosaroma and liposarcoma.
Abbreviations: STS, soft tissue sarcoma; ORR, objective response rate; mPFS, median progression free survival; mOS, median overall survival; ALT, alanine aminotransferase.
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doxorubicin (75 mg/m2 every 3 weeks) were combined with 
olaratumab 15 mg/kg IV day 1 and 8 for every 3 weeks.16 
Interim OS analysis showed an impressive difference of 25.0 
vs 14.7 months (hazard ratio [HR] =0.44, P=0.0005) in favor 
of the combination therapy. There was no significant differ-
ence in objective response rate (ORR), 18.8% and 12.3%, 
respectively, for the combination and single-agent arms. The 
Phase III study has nearly completed enrollment.
Gemcitabine–docetaxel
In patients with metastastic leiomyosarcoma, especially uterine 
leiomyosarcoma, the combination of fixed-dose gemcitabine 
(900 mg/m2 IV day 1 and 8q21days) with docetaxel (100 mg/
m2 IV day 8q21days) is used based on three Phase II studies 
in patients with advanced or metastatic leiomyosarcoma.17–19 
For patients with uterine leiomyosarcoma, response rates 
ranged between 24% and 52%. However, the best response 
rate in patients with nonuterine leiomyosarcoma was only 5%. 
Recently, a Phase III study was published comparing gem-
citabine and docetaxel plus bevacizumab vs gemcitabine and 
docetaxel plus placebo as first line in 107 patients with uterine 
leiomyosarcoma. No differences between the two study arms 
were reported. Response rates were 35.8% and 31.5%, median 
PFS was 4.2 and 6.2 months, and median OS was 23.3 and 26.9 
months for the placebo vs the bevacizumab arm, respectively.20 
The results of the UK GeDDIS trial have been presented at 
the ASCO annual meeting in 2015. In this Phase III trial, 
257 patients with STS were randomized between doxorubicin 
75 mg/m2 q21days or the combination of gemcitabine 650 mg/
m2 day 1 and 8q21days and docetaxel 75 mg/m2 every 21 days. 
No significant difference in median PFS (23 and 24 weeks, 
respectively) or median OS (71 and 63 weeks, respectively) 
was reported. Subgroup analysis showed no benefit for patients 
with leiomyosarcoma treated with gemcitabine–docetaxel 
compared to other histological subtypes. The full paper is not 
yet published.21 A Phase II trial is currently recruiting and ran-
domizing patients with advanced/metastatic leiomyosarcoma 
to trabectedin or gemcitabine–docetaxel (NCT02249702).
Taxanes
In patients with advanced or metastatic angiosarcoma, 
taxanes have shown efficacy, based on the results of several 
retrospective studies and Phase II trials. These include pacli-
taxel in a weekly or 3-weekly schedule and docetaxel in a 
3-weekly schedule.22–27 Response rates vary between 7% and 
89% (best response rates in facial and scalp angiosarcoma) 
and median OS between 7 and 9.5 months.22–27 A recent 
Phase II study combining paclitaxel with bevacizumab vs 
single-agent paclitaxel in angiosarcoma did not show a benefit 
for the combination.28
Metronomic cyclophosphamide and prednisolone
In elderly frail patients with advanced or metastatic STS, unfit 
for standard first-line therapy with doxorubicin or combina-
tion of doxorubicin and ifosfamide, the combination of oral 
cyclophosphamide 100 mg twice daily and prednisolone 20 
mg daily from day 1 to 7 every 14 days has been reported 
to show benefit. In a retrospective study performed at the 
Institut Gustave Roussy, the response rate was 26.9%, disease 
control rate was 69.2%, and median PFS was 6.8 months.29 
Further studies are required to define the precise role of this 
schedule in patients with advanced/metastatic STS. Lympho-
penia, anemia, and thrombocytopenia were the most common 
reported adverse events.
Beyond first line of systemic therapy
After failure to first-line therapy, several systemic options are 
available, and the selection of a specific schedule is made on 
the basis of individual patient-based considerations, including 
expected toxicity, tumor burden, and histological subtype. In 
a recent review by the Royal Marsden Hospital Sarcoma Unit, 
a proposal for sequencing therapy was published.12
Ifosfamide
As a monotherapy, the alkylating agent ifosfamide has 
activity varying from 4.8% to 62.5%.30 In subsequent 
studies, ifosfamide consistently yielded response rates of 
approximately 20%–25% in the metastatic setting, with a 
median OS duration of 1 year, results comparable to those 
obtained with doxorubicin.31 Several doses and schedules 
of ifosfamide have been investigated in STS patients. There 
is a clear dose–response relationship with this agent, and 
consequently higher doses up to 12–18 g/m2 and prolonged 
dosing schedules have been studied. Dose-limiting toxici-
ties are bone marrow suppression, hemorrhagic cystitis, and 
encephalopathy. A randomized trial comparing two different 
schedules of ifosfamide 9 g/m2 to doxorubicin demonstrated 
no advantage for ifosfamide over doxorubicin.32 In a large 
retrospective analysis of the EORTC Soft Tissue and Bone 
Sarcoma Group, synovial sarcomas showed a higher response 
rate on ifosfamide-containing regimens than on doxorubi-
cin.33 Prolonged infusion of ifosfamide (1 g/m2/d for 14 days 
in cycles of 28 days) has retrospectively been reported in 35 
STS patients with encouraging results. Partial response was 
seen in 20% of the patients, and stable disease in another 
29%. In the subgroup with dedifferentiated liposarcoma 
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(n=22), the partial response rate was 22.7% and stable disease 
in 31.8%. Median PFS and OS were 4.2 and 11.2 months, 
respectively. The most common toxicities were fatigue, 
nausea, and vomiting.34
Gemcitabine
Gemcitabine is an antimetabolite of pyrimidine. In unselected 
STS, a weekly gemcitabine schedule with 1,000–1,250 mg/
m2 administered in 30 minutes with a pause week every 3–4 
weeks is most frequently used. In six gemcitabine mono-
therapy Phase II studies with pretreated unselected STS, 
ORRs of 3.2%–27% were reported. Median PFS varied 
between 1.5 and 6.3 months and median OS between 7.2 
and 20 months.19,35–39 Most frequently occurring toxicities are 
hematologic toxicities, increased alanine aminotransferase 
levels, myalgia, and rash.
Dacarbazine
Dacarbazine is an alkylating agent and is administered 
1.2 g/m2 every 3 weeks IV as a monotherapy. In three second-
line Phase II trials, the response rate was 4%–18%, with a 
median PFS of 2 months and a median OS of 8.2 months.40–42 
Most reported toxicities are hematologic toxicities, nausea, 
vomiting, flulike symptoms, and diarrhea.40
Recently, dacarbazine was the standard arm in compari-
son to trabectedin in a large Phase III study for patients with 
metastatic liposarcoma or leiomyosarcomas after failure of 
conventional chemotherapy. The dacarbazine group had a 
median PFS of 1.5 months and a median OS of 12.9 months.43 
This trial is discussed in more detail in the “Trabectedin” 
section.
Dacarbazine (500 mg/m2 q2weeks) has been combined 
with gemcitabine (1,800 mg/m2 q2weeks) in two Phase II 
trials, of which one randomized against single-agent dacar-
bazine.41,42 For the combination, median PFS was 4.2 months 
and median OS 16.8 months in the randomized Phase II trial. 
Despite hematologic toxicities, fatigue, nausea, vomiting, and 
stomatitis were the most reported adverse events.
Eribulin
Recently, the results of a Phase III trial comparing eribulin 
to dacarbazine were published.44 A total of 452 patients with 
intermediate- or high-grade advanced liposarcoma or leio-
myosarcoma who had received at least two previous systemic 
regimens for advanced disease (including an anthracycline) 
were  randomized 1:1 to eribulin mesilate (1.4 mg/m2 IV on 
days 1 and 8) or dacarbazine (850–1,200 mg/m2 IV on day 1) 
every 21 days until disease progression. OS was significantly 
improved in patients assigned to eribulin compared with those 
assigned to dacarbazine (median OS =13.5 vs 11.5 months; 
HR =0.77). This OS benefit was only seen in liposarcoma 
patients (median OS =15.6 vs 8.4 months, respectively) and 
not in those with leiomyosarcoma (12.7 vs 13.0 months). 
However, this study was not powered for such subgroup 
analyses. Median PFS was similar in both treatment groups: 
2.6 months. Most reported adverse events for eribulin were 
fatigue, nausea, alopecia, constipation, leukopenia, neutro-
penia, and anemia.
Pazopanib
Currently, the tyrosine kinase inhibitor pazopanib is the 
only targeted therapy approved for advanced or metastatic 
nonadipocytic, non-GIST STS after failure of standard 
chemotherapy. Pazopanib has activity against VEGFR1–2, 
PDGFR A–B, and KIT. In the PALETTE study,11 369 patients 
were randomized 2:1 to receive pazopanib 800 mg once 
daily orally or placebo. Median PFS was significantly longer 
in the pazopanib arm, 4.6 vs 1.6 months (HR =0.31, 95% 
CI =0.24–0.40, P<0.0001), but no significant difference in 
median OS was found (12.5 vs 10.7 months, HR =0.85, 95% 
CI =0.67–1.11, P=0.25). Partial responses were seen in 6% of 
the patients on pazopanib, and another 67% had stable disease 
as best response. Most reported adverse events were fatigue, 
diarrhea, nausea, weight loss, and hypertension. Quality of 
life did not differ between both arms but was only monitored 
during the first 12 weeks of treatment.
Trabectedin: pharmacology, mode 
of action, pharmocokinetics, toxicity, 
and registration
Trabectedin (Yondelis®, Janssen Biotech, Inc, Horsham, 
PA, USA) is a tetrahydroisoquinoline, which was originally 
isolated from the Caribbean tunicate Ecteinascida turbinata 
and is currently produced synthetically.45
Trabectedin has several modes of action. Unlike clas-
sical alkylating chemotherapeutic drugs, which bind to the 
major DNA groove, trabectedin binds to specific selected 
triplets of the DNA minor groove. This results in a distor-
tion of the double helix structure and causes double-strand 
breaks, leading to tumor cell apoptosis. Part of the molecule 
protrudes out of the DNA and interacts with proteins at the 
site of the adduct, such as XPG and RNA polymerase II 
(Pol II). This results in inhibition of transactivated transcrip-
tion in a nucleot ide excision repair-dependent manner.46,47 
This impact on transcription is especially of interest in 
translocation-related sarcomas, such as myxoid liposarcoma 
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and Ewing sarcoma. In myxoid liposarcomas, the presence 
of t(12;16) or t(12;22) translocations leads to FUS-CHOP 
or EWS-CHOP fusion proteins. Trabectedin displaces these 
fusion proteins from its target promoters, resulting in the dif-
ferentiation of myxoid liposarcoma cells into normal adipo-
cytes.48 In Ewing sarcoma, the translocation t(11;22) results 
in an oncogenic fusion gene EWS-FLI1, a crucial driver for 
the oncogenic transformation and survival of Ewing sarcoma 
cells. Trabectedin has a specific inhibitory effect on the 
aberrant transcriptional activity of this oncogenic chimera, 
thereby reversing the gene signature of induced downstream 
targets of EWS-FLI1 and inducing apoptosis.49,50
Apart from these molecular mechanisms, trabectedin also 
influences the tumor microenvironment. Trabectedin induces 
rapid apoptosis exclusively in mononuclear phagocytes (mac-
rophages and monocytes), with a subsequent strong decrease 
in the production of several cytokines and chemokines such as 
IL-6, CCL2, CXCL8, Angiopoietin 2, and VEGF. This results 
not only in diminished tumor growth, but also in inhibition 
of tumor angiogenesis and modulation of stroma-mediated 
resistance to therapy.46
Trabectedin is administered IV. The approved schedule 
is a 24-hour supply using a central venous catheter. Shorter 
schedules (eg, 1 or 3 hours) have been tested, but have not 
shown benefit.51–53 Trabectedin has a high volume of distri-
bution since 94%–98% of trabectedin within the plasma is 
bound to albumin. Trabectedin is metabolized by the cyto-
chrome P450 system, especially CYP3A4. Less than 1% is 
eliminated unchanged in the urine. The terminal half-life 
time is long, approximately 180 hours. A population phar-
macokinetic analysis indicated that the plasma clearance of 
trabectedin is not influenced by age, sex, total body weight, 
or body surface area. There are no data available in patients 
with a creatinine clearance below 30 mL/min. The mode of 
metabolism and elimination suggest no significant impact 
of decreased renal function. The impact of hepatic failure 
on trabectedin pharmacokinetics is unclear, but because of 
its toxicity profile with (sometimes) highly elevated hepatic 
enzyme levels, caution is warranted.54
The most common adverse events of trabectedin are neu-
tropenia (50% ≥ grade 3), thrombocytopenia (13% ≥ grade 3), 
anemia (13% ≥ grade 3), anorexia, nausea, vomiting, diarrhea or 
constipation, fatigue, asthenia, hyperbilirubinaemia (1% grade 
3), and elevated ALT (41% ≥ grade 3) or aspartate aminotrans-
ferase (AST) (51% ≥ grade 3), or creatinine phosphokinase 
(4% ≥ grade 3).54 Trabectedin is administered until progres-
sive disease or intolerability. Recently, a randomized Phase II 
study was reported, which compared interruption of trabectedin 
after six cycles in patients with responding or stable disease 
to continuation of trabectedin and found a worse PFS in the 
discontinuation group (PFS at 6 months after randomization 
23.1% vs 51.9%, respectively).55
In Europe, trabectedin is approved by European Medicines 
Agency for advanced STS after failure of anthracyclines. In 
the United States, the US Food and Drug Administration 
approved trabectedin in November 2015 for the treatment 
of patients with unresectable or metastatic liposarcoma or 
leiomyosarcoma previously treated with an anthracycline-
containing regimen, on the basis of the randomized trial 
comparing dacarbazine to trabectedin.43 Furthermore, it is 
registered for relapsed ovarian cancer in combination with 
pegylated liposomal doxorubicin.
Trabectedin in sarcoma: efficacy
Efficacy in first line
In three Phase II/IIb trabectedin studies in chemotherapy 
naïve unselected STS patients, response rates were moderate 
(10%–17.1%) and median PFS was short (1.6–5.8 months). 
Median OS data are not yet available (Table 2).52,56,57 In the 
TRUSTS study, a direct comparison with doxorubicin was 
made.52 There were no significant differences in ORR, median 
PFS, or median OS. As already mentioned, response rates for 
single-agent treatment with doxorubicin vary between 16% 
and 27%. Median OS varies between 7.7 and 12 months.14 
Taken together, in unselected advanced or metastatic STS, 
there is no evidence to choose trabectedin above the regular 
standard first-line therapy with doxorubicin.
A Phase III trial in 121 translocation-related sarcomas 
did not show any superiority for either doxorubicin or tra-
bectedin in a direct comparison between those two drugs.58 
Again, ORRs were numerically higher in doxorubicin-treated 
patients (27% vs 5.9%), although this was not statistically 
significant.
Beyond first-line systemic treatment
In four Phase II trials in unselected, pretreated, STS patients, 
the reported response rates were 2.8%–8%, median PFS was 
1.7–3.5 months, and median OS was 9.2–12.8 months for 
trabectedin.59–62
A randomized Phase II study comparing trabectedin to 
best supportive care in translocation-related sarcomas showed 
a significantly better response rate (8% vs 0%), longer median 
PFS (5.6 vs 0.9 months, HR =0.07), and longer median OS 
(not reached vs 8 months, HR =0.42).63 A large Phase II 
study in 270 patients with liposarcoma or leiomyosarcoma 
compared two different trabectedin schedules. Again, low 
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Table 2 Results of trabectedin trials in STS patients
Reference Phase Design n RR (%) TTP 
(months)
PFS (months) OS (months)
70 I Japanese STS pts, after 
failure of anthracyclines, 
dose escalation, MTD 
1.2 mg/m2 q21day
15 20 NA NA NA
56 II TRB 1.5 mg/m2 24 hq21 
STS first-line STS
35 17.1 – 1.6 15.8
57 II TRB 1.5 mg/m2 q21d, 
u-LMS, first-line STS
20 10 4.5 5.8 >26.1 (median not 
reached)
52 IIb Doxo vs TRB 3 vs TRB 
24 hours first-line STS
133 Doxo: 25.6 TRB 
3 hours: 14.8
TRB 24 hours: 
7.6 NS
– Doxo: 5.5
TRB 3 hours: 2.8
TRB 24 hours: 3.1 
NS
TRB 24 hours vs doxo 
HR 0.94 NS
TRB 3 hours vs 
doxo HR 1.30 NS 
(preliminary analysis)
59 II TRB 1.5 mg/m2 24h q21 
pretreated STS
99 8 – 3.5 9.2
62 II TRB 1.5 mg/m2 24h q21 
pretreated STS
36 8 – 1.7 12.1
60 II TRB 1.5 mg/m2 24h q21 
pretreated STS
54 4 – 1.9 12.8
61 II TRB 1.3–1.65 mg/m2 
3hq21 + dexamethasone 
or placebo, pretreated 
STS
35 2.8 – 2.1 10.2
51 II TRB 1.5 mg/m2 
q3weeks vs TRB 0.58 
mg/m2 3 hours day 1, 
8, 15 every 4 weeks. 
L-sarcoma, after failure 
anthracyclines and 
ifosfamide
270 5.6 vs 1.6 3.7 vs 2.3, 
HR =0.73, 
P=0.03
3.3 vs 2.3, HR =0.76, 
P=0.04
13.9 vs 11.8, HR =0.84, 
P=0.19
63 II TRB 1.2 mg/m2 q3wk 
vs best supportive care 
in translocation-related 
sarcoma after standard 
chemotherapy
76 8 vs 0 – 5.6 vs 0.9, HR =0.07, 
P<0.0001
Not reached vs 8.0, HR 
=0.42, P=0.04
68 II TRB 1.5 mg/m2 q21d 
neoadjuvant myxoid 
liposarcoma
23 24 2 patients pCR
58 III TRB 1.5 mg/m2 q21 
vs doxorubicin in 
translocation-related 
sarcoma 
121 5.9 TRB vs 27 
doxo
– HR 0.85 NS HR 0.77 NS 
(preliminary analysis)
43 III
IA
TRB 1.5 mg/m2 q21 
vs dacarbazin in 
L-sarcomas after 
anthracycline and one 
additional chemotherapy
518 9.9 vs 6.9 – 4.2 vs1.5, HR =0.52, 
P<0.0001
12.9 vs 12.4, HR =0.87, 
P=0.37
64 IVa TRB 1.5 mg/m2 q3wk. 
All STS after standard 
chemotherapy
807 evaluable 
out of 1,895. 
476/807 
L-sarcoma
All 5.9
L 6.9
2.3 – All 11.9
L-sarcoma 16.2
Note: aWorldwide expanded access program study.
Abbreviations: IA, interim analysis; L-sarcoma, liposarcoma and leiomyosarcoma; RR, response rate; TTP, time to progression; PFS, progression free survival; OS, overall 
survival; STS, soft tissue sarcoma; TRB, trabectedine; MTD, maximum tolerated dose; q, every; doxo, doxorubicin; HR, hazard ratio; NS, not significant; pCR, pathological 
complete response; NA, not applicable.
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response rates (5.6%) and short median PFS (3.3 months) 
with a median OS of 13.9 months were found in the now 
regular dosing arm of 1.5 mg/m2 every 3 weeks.51
Recently, the results of a Phase III trial with trabectedin 
vs dacarbazine in patients with L-sarcomas progressive 
after anthracyclines and one other prior chemotherapy were 
reported.43 A total of 518 patients were enrolled and ran-
domly assigned to either trabectedin (n=345) or dacarbazine 
(n=173). Median PFS for trabectedin vs dacarbazine was 
4.2 vs 1.5 months, HR =0.55, P<0.001). In the predefined 
subanalyses, all subgroups benefited from trabectedin, 
although the benefit was not statistically significant in all 
these subgroups. The interim analysis of OS (64% censored) 
demonstrated a nonsignificant 13% reduction in risk of death 
in the trabectedin arm compared with dacarbazine (median 
OS for trabectedin vs dacarbazine, 12.4 vs 12.9 months, 
HR =0.87, P=0.37).
In conclusion, only a modest difference in the efficacy 
of trabectedin in translocation-related sarcomas compared to 
unselected STS (also including translocation-related STS) 
has been observed (both in the first and subsequent lines of 
therapy). More convincing results for translocation-related 
sarcomas compared to unselected STS were found in the 
expanded access trial.64 In this trial, STS patients progressive 
after standard chemotherapy were treated with trabectedin 
1.5 mg/m2 every 3 weeks. Four hundred and seventy six of 
the 807 (59%) assessable patients had “liposarcoma and 
leiomyosarcoma (L-sarcomas)”. The ORR of the total of 
807 patients was 5.9% (95% CI =4.4–7.8). For patients with 
L-sarcomas (n=476), the ORR was 6.9% (95% CI =4.8–9.6), 
whereas patients classified as non-L-sarcoma (n=302) had 
an ORR of 4.0% (95% CI =2.1–6.8). A total of 258 patients 
with L-sarcoma experienced CR, PR, or stable disease, a 
clinical benefit rate of 54%, compared with 114 patients 
with non-L-sarcoma (the clinical benefit rate of 38%). Nine 
hundred and three patients were evaluable for OS. In the total 
group, median OS was 11.9 months; in the group of patients 
with L-sarcomas (n=509) median OS was 16.2 months (95% 
CI =14.1–19.5), and in the non-L-sarcoma patients median 
OS was 8.4 months (95% CI =7.1–10.7). Patients with lipo-
sarcoma (n=184) had a 2 months longer median survival than 
those with leiomyosarcoma (n=325; 18.1 vs 16.2 months).64
Combinations of trabectedin in STS
The combination of trabectedin and doxorubicin has been 
studied in two Phase I trials and one Phase II trial (Table 3).65–
67 Both Phase I studies in unselected STS patients concluded 
the recommended Phase II dose of doxorubicin as 60 mg/
m2 every 3 weeks. For trabectedin, the recommended dose in 
one study65 was 0.7 g/m2 in 3 hours every 3 weeks, and in the 
other study 1.1 g/m2 in 3 hours every 3 weeks.66 Dose-limiting 
toxicities were thrombocytopenia, (febrile) neutropenia, 
and asthenia. The difference in recommended trabectedin 
dose seems to be explained by the difference in accepted 
pretreatments. Patients in the study assessing the 0.7 g/m2 
dose65 were heavily pretreated, while in the 1.1 g/m2 study66 
0–1 prior treatments were allowed and, therefore, only seven 
out 41 patients had received prior systemic therapy. Other 
more frequently occurring toxicities were increased ALT/
AST, nausea, vomiting, and stomatitis. The ORR in the two 
Phase I trials was 12%–17.9%, which is numerically higher 
than the response rate of single-agent trabectedin but lower 
Table 3 Combinations of trabectedin in STS patients
Reference Phase Design n RR (%) TTP 
(months)
PFS (months) OS (months)
69 I TRB 0.9 mg/m2 d1 and 
gemcitabine 700 mg/m2 
d1+8q21days
5*
65 I RD TRB 0.7 mg/m2 
3 hours and doxorubicin 
60 mg/m2 q21, pretreated STS 
and breast cancer
29 STS 17.9 12.5 NA NA
66 I MTD TRB 1.1 mg/m2 3 hours 
and doxorubicin 60 mg/m2 q21 
STS 0–1 prior chemotherapy 
other than anthracyclines
41 12 9.2 Not reached, >14.8
67 II TRB 1.1 mg/m2 in 3 hours and 
doxorubicin 60 mg/m2 q21day. 
First line, u-LMS, and STS-LMS
109 u-LMS 59.6
STS-LMS 39.4
u-LMS 6.6
STS-LMS 
12.5
u-LMS 8.2
STS-LMS 12.9
u-LMS 20.2
STS-LMS 34.5
(median follow up 9.9 and 14.5)
Note: *Not tolerated; 4/5 patients DLT.
Abbreviations: u-LMS, uterine LMS; RD, recommended dose; MTD, maximum tolerated dose; TRB, trabectidin; LMS, leiomyosarcoma; STS, soft-tissue sarcoma; RR, 
response rate; TTP, time to progression; PFS, progression free survival; OS, overall survival ; DLT, dose limiting toxicity; q, every; NA, not applicable.
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than the response rate of single-agent doxorubicin when 
administered as first-line therapy.
In a French Phase II trial, previously untreated patients 
with advanced or metastatic uterine leiomyosaroma (u-LMS, 
n=47) or soft-tissue leiomyosarcoma (STS-LMS, n=61) were 
treated with doxorubicin 60 mg/m2 and trabectedin 1.1 g/m2 
in 3 hours every 3 weeks up to six cycles.67 High ORRs were 
found: 59.6% for u-LMS and 39.4% for STS-LMS. The most 
common grade 3–4 treatment-associated adverse events were 
(febrile) neutropenia, thrombocytopenia, anemia, increased 
ALT, and fatigue.
The combination of doxorubicin and trabectedin seems 
promising. The high ORR suggests a potential role in a neoad-
juvant setting. So far, only one study on single-agent trabect-
edin in the neoadjuvant setting for myxoid liposarcoma has 
been published, reporting a response rate of 24%.68 Another 
point of interest would be the continuation of trabectedin after 
the six cycles of combined trabectedin and doxorubicin since 
a very recent study of Le Cesne et al55 found that continued 
trabectedin in patients with disease control after six cycles 
is superior to restarting treatment at progression.
The combination of trabectedin and gemcitabine has 
proven to be not tolerable.69 A phase Ib trial in pretreated 
STS patients treated with a combination of trabectedin and 
olaparib, a PARP inhibitor, is now open for recruitment 
(NCT02398058).
Conclusion
In conclusion, trabectedin has consistent activity in all 
types of STS. Trabectedin can be positioned after failure of 
first-line therapy with anthracyclines or in patients unfit for 
anthracycline-based therapy. There is no rationale to replace 
anthracycline-based first-line therapy with trabectedin cur-
rently, since trabectedin has not demonstrated a survival or 
response rate advantage over doxorubicin.
The combination of doxorubicin and trabectedin deserves 
further study as first-line palliative therapy as well as in the 
neoadjuvant setting. This is also the case for trabectedin 
maintenance therapy after induction therapy with six cycles 
of doxorubicin.
For second-line and further therapy, no preferred 
sequence suiting for all STS subtypes can be provided. The 
choice should be made on an individual basis, taking into 
account the histological subtype, aim of the treatment, and 
the expected toxicity. Unfortunately, almost no quality-of-
life data are available for the different chemotherapeuti-
cal options. Future studies should include quality-of-life 
measurements.
Beyond first-line treatment, trabectedin has the advantage 
of a relatively favorable toxicity profile, but the disadvantage 
of the need of a central venous catheter and the 24 hours 
administration. Based on the expanded access program data, 
there is more rationale in translocation-related sarcomas for 
the use of trabectedin in terms of efficacy. In these sarcomas, 
it seems reasonable to place trabectedin as second-line treat-
ment. In other sarcomas, several options can be considered 
including trabectedin.
Opportunities for the near future will be the investigation of 
maintenance therapy with trabectedin after doxorubicin induc-
tion therapy and combinations of trabectedin and doxorubicin.
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